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Outcomes for patients with COVID-19 infection have been 
idely reported for the initial peak of the pandemic. 1 However, 
here is a lack of data describing outcomes and characteristics of 
eadmitted patients in the resurgent peak, after corticosteroids be- 
ame standard of care. 
Based on data and protocols from randomised controlled trials, 
ost international treatment guidelines recommend 6 mg dexam- 
thasone daily (or equivalent) for up to 10 days in those hospi- 
alised with severe COVID-19 but stopping on discharge. 2–6 
The UK’s second COVID-19 wave peaked on 9/1/2021. 7 Here we 
escribe the characteristics of patients admitted, discharged and 
eadmitted, due to COVID-19, to our hospital, during this second 
ave. We explored the relationship between clinical and biochem- 
cal variables, treatment received during a patient’s first admission, 
nd readmission risk, in relation to corticosteroid use. 
ethods 
We reviewed patients admitted from the community to Univer- 
ity College Hospital (UCH) with COVID-19 as their primary diag- 
osis between 1st-31st December 2020. Re-attendance and read- 
ission data were collected for patients who re-presented within 
0 days following discharge from their first admission. 
Data were retrospectively collected, including patient demo- 
raphics, clinical data on first admission and readmission, steroid 
reatment and any treatment received on discharge from the first 
dmission. 
In the primary analysis, appropriate corticosteroid dosage was 
efined as receiving 6 mg dexamethasone daily. Statistical analy- 
is was conducted in Stata ver. 12.1 (StataCorp). Independent data 
ere compared using Mann-Whitney U test or t -test. Paired data 
ere compared by Wilcoxon signed-rank and proportions by χ2 
est. 
We fitted a logistic regression model to assess relationships 
etween demographic and clinical factors and readmission risk. 
e conducted a sensitivity analysis considering anyone receiving 
 dose equivalent to 75% of 6 mg dexamethasone daily as hav- 
ng received steroids, using the outcome of readmission or re- 
ttendance. 
The study met the NHS definition of a quality improvement 
roject with the departmental governance lead and did not require 
thical approval. ttps://doi.org/10.1016/j.jinf.2021.03.002 
163-4453/© 2021 The British Infection Association. Published by Elsevier Ltd. All rights results 
271 patients were admitted to UCH with COVID-19 in Decem- 
er. 25 patients were transferred from external hospitals or had 
osocomially-acquired COVID-19 and 50 patients died during their 
rst admission or remained an inpatient throughout the data col- 
ection period and were excluded from subsequent analysis. 196 
atients were included in the analysis. 
Median age was 58 years (IQR 47–71); 48% female; 133/196 
67.9%) had ≥1 comorbidity (as defined by the ISARIC 4C score), 8 
2 (16.3%) had diabetes mellitus. Median length of stay was 4 days 
IQR 2–8). 125/196 (63.8%) required oxygen of whom 30 (15.3%) re- 
uired respiratory support. 124/196 (63.3%) received corticosteroids 
n their first admission for a median of 5 days (IQR 3–8). All 
atients had acceptable peripheral oxygen saturations (SpO 2 ) at 
ischarge( ≥92% on air or within their target range). 10/196 (5.1%) 
ere discharged with corticosteroids. 53/196 (27.0%) were followed 
p in a virtual clinic post-discharge. 
26/196 (13.3%) patients re-attended UCH due to COVID-19, a 
edian of 3 days (IQR 2–5) following discharge. Of these, 20 
10.2%) were readmitted. Median CRP (mg/L) rose significantly in 
hose readmitted from 43.2 (IQR 29.4–71.6) on discharge to 91.8 
IQR 37.3–139.6) on readmission ( p = 0.021). 17/20 (85%) required 
xygen and corticosteroids on readmission of whom 6 (30%) re- 
uired respiratory support. 
The 11/20 patients receiving steroids during their first admis- 
ion, subsequently readmitted, had a shorter initial admission (me- 
ian 2 days [IQR 1–3] vs 5 days [3–9] p = 0.005), received shorter 
ourses of steroids (median 2 days [IQR 1–3] vs 5 days [3–8] 
 < 0.001) and were discharged earlier in their illness course (me- 
ian day 8 [IQR 6–11] vs day 13 [IQR 9–18], p = 0.005) than those
hat were not readmitted. There was no difference in SpO 2 on air 
t discharge (95% IQR [94%–96%] for both) or in remdesivir use 
27.2% vs 33.6%, p = 0.669) . Data for patients receiving inpatient 
orticosteroids on their first admission were quartiled based on 
heir duration of steroids. In the first quartile, (1–3 days) read- 
ission rates were highest at 25% ( Fig. 1 and Table 1 ). In an ex-
loratory logistic regression analysis, only treatment with dexam- 
thasone significantly reduced odds of readmission (OR 0.77 per 
ay of dexamethasone 95% CI 0.61–0.92, p = 0.012). Results were 
imilar in the sensitivity analysis considering both equivalent doses 
f other steroids and both re-attendance and readmission to hos- 
ital (supplementary data). 
iscussion 
To our knowledge this is the first study to evaluate readmission 



















































































Patients admitted from the community who were discharged alive from their first admission. Excluding ITU transfers and nosocomial transmissions. Comparing characteristics of those receiving different steroid course 
durations by quartile ( n = 196). 
Characteristics 
Number of days of dexamethasone received as inpatient on 1st admission 
Did not receive ( n = 72) 1st Quartile1–3 ( n = 40) 2nd Quartile4–5 ( n = 26) 3rd Quartile6–8 ( n = 32) 4th Quartile ≥9 ( n = 26) 
Number readmitted (%) 9 (12.5) 10 (25.0) 0 (0.0) 0 (0.0) 1 (3.8) 
Median age (IQR) - years 61 (49–78) 51 (41–65) 56 (40–66) 64 (48–70) 55 (49–67) 
Sex 
Males (%) 37 (51.4) 23 (57.5) 12 (46.2) 15 (46.9) 15 (57.7) 
Females (%) 35 (48.6) 17 (42.5) 14 (53.8) 17 (53.1) 11 (42.3) 
Ethnicity (%) 
White 27 (37.5) 19 (47.5) 10 (38.5) 10 (31.3) 9 (34.6) 
Black 11 (15.3) 8 (20.0) 1 (3.8) 5 (15.6) 5 (19.2) 
South Asian 7 (9.7) 1 (2.5) 3 (11.5) 3 (9.4) 3 (11.5) 
Other Asian 7 (9.7) 0 (0.0) 3 (11.5) 1 (3.1) 2 (7.7) 
Unknown 20 (27.8) 12 (30.0) 9 (34.6) 13 (40.6) 7 (26.9) 
Median day of illness on admission (IQR) 4 (2–8) 7 (4–9) 8 (5–10) 8 (5–10) 8 (6–9) 
Median length of admission (IQR) - days 2 (1–5) 2 (2–3) 4 (4–5) 7 (6–8) 10 (9–13) 
Number of comorbidities (%) 
0 22 (30.6) 15 (37.5) 11 (42.3) 8 (25.0) 7 (26.9) 
1 19 (26.4) 8 (20.0) 7 (26.9) 11 (34.4) 11 (42.3) 
> 2 31 (43.1) 17 (42.5) 8 (30.8) 13 (40.6) 8 (30.8) 
Number with infiltrates of Chest X-ray (%) 34 (47.2) 34 (85.0) 23 (88.5) 31 (96.9) 26 (100.0) 
Number of asymptomatic COVID (%) 18 (25.0) 0 (0.0) 0 (0.0) 1 (3.1) 0 (0.0) 
Median admission sats (IQR) -% 97 (95–98) 93 (91–97) 92 (90–95) 92 (88–95) 92 (88–94) 
Median CRP on admission (IQR) – mg/L 24.0 (8.0–63.4) 41.2 (24.8–77.5) 68.0 (51.8–102.8) 102.1 (59.8–168.9) 98 (73–164) 
Median Urea on 1st admission (IQR) – mmol/L 4.5 (3.6–6.9) 4.2 (3.5–5.9) 4.5 (3.5–5.6) 4.4 (3.3–6.3) 6.0 (4.8–7.3) 
Median lymphocytes on 1st admission (IQR) – x10 9 /L 1.01 (0.80–1.47) 1.06 (0.79–1.32) 0.87 (0.63–1.23) 0.87 (0.69–1.31) 1.00 (0.73–1.10) 
Median peak oxygen requirement (IQR) -% 21 (21–21) 28 (24–33) 32 (32–36) 40 (35–53) 60 (40–64) 
Number of patients by peak respiratory support (%) 
Hospitalised, no oxygen 61 (84.7) 8 (20.0) 1 (3.8) 1 (3.1) 0 (0.0) 
Oxygen by mask or nasal prongs 10 (13.9) 31 (77.5) 24 (92.3) 20 (62.5) 9 (34.6) 
NIV or high-flow oxygen 1 (1.4) 0 (0.0) 1 (3.8) 11 (34.4) 16 (61.5) 
Intubation and Mechanical Ventilation 0 (0.0) 1 (2.5) 0 (0.0) 0 (0.0) 1 (3.8) 
Ventilation and additional organ support (Pressors, RRT, ECMO) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
Number receiving remdesivir (%) 0 (0.0) 6 (15.0) 11 (42.3) 11 (34.4) 13 (50.0) 
Median CRP on discharge from 1st admission (IQR) – mg/L 22.5 (4.6–53.9) 28.0 (16.3–62.2) 19.9 (13.2–41.4) 16.8 (10.2–31.1) 12 (5.3–40.6) 
% Sats drop on exercise at discharge from 1st admission (%) 
0–1 21 (29.2) 14 (35.0) 10 (38.5) 10 (31.3) 6 (23.1) 
2–3 2 (2.8) 8 (20.0) 5 (19.2) 5 (15.6) 3 (11.5) 
≥4 5 (6.9) 3 (7.5) 7 (26.9) 4 (12.5) 11 (42.3) 
Unknown 44 (61.1) 15 (37.5) 4 (15.4) 13 (40.6) 6 (23.1) 
Number discharged with steroids on 1st admission (%) 2 (2.8) 6 (15.0) 1 (3.8) 0 (0.0) 1 (3.8) 
Number discharged with thromboprophylaxis on 1st admission (%) 6 (8.3) 3 (7.5) 3 (11.5) 7 (21.9) 7 (26.9) 
Number discharged with saturations probe on 1st admission (%) 8 (11.1) 10 (25.0) 6 (23.1) 3 (9.4) 6 (23.1) 
Median ISARIC 4C mortality% (IQR) 11.7 (4.8–19.2) 7.8 (2.3–19.2) 11.7 (4.8–19.2) 19.2 (11.7–26.9) 14.4 (7.8–26.9) 
Median ISARIC 4C deterioration%(IQR) 18.4 (12.3–24.4) 29.4 (20.1–44.9) 46.7 (26.6–59.7) 56.4 (35.9–65.7) 57.4 (40.3–65.4) 
Number receiving telephone clinic follow up on 1st admission (%) 19 (26.4) 16 (40.0) 12 (46.2) 3 (9.4) 3 (11.5) 
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Fig. 1. Survival plot showing the probability of being out of hospital in the 10 days 
following discharge by duration of corticosteroids received during initial admission. 
The line showing readmission in the group receiving steroids for 4–5 days is not 
visible as masked by the line for steroids for 6–8 days – i.e. there were no readmis- 














































Despite the majority meeting safe discharge criteria, the read- 
ission rate is significant, but concordant with rates from the first 
ave in similar hospitals 9 . Readmitted patients presented to and 
ere discharged from hospital earlier in their COVID-19 illness 
han patients who were not readmitted. They returned to hospi- 
al after a short time after reaching their illness peak, displaying a 
roinflammatory phenotype as evidenced by their rising CRP. Sig- 
ificant oxygen requirements were observed and an appreciable 
roportion of patients required respiratory support. 
Shorter courses of steroids on first admission increased risk of 
eing readmitted to hospital with COVID-19. Those who received 
–3 days of steroids experienced quick clinical improvement and 
ere discharged from hospital and corticosteroids were stopped at 
ischarge. 25% of this subgroup were readmitted. 
Our data suggest that short courses of corticosteroids may not 
e sufficient for patients requiring hospital admission with severe 
OVID-19. As patients are readmitted with evidence of ongoing 
nflammation, it is biologically plausible that increasing corticos- 
eroid duration would reduce the chance of deterioration post- 
ischarge. Many hospitals have now instigated virtual follow up 
ith daily calls. It is therefore reasonable to consider continuing 
 course of corticosteroids after hospital discharge as treatment 
an be given within these frameworks to monitor side-effects of 
teroids. UK national guidelines now recognise that patients may 
e discharged to a virtual ward where continuation of steroids may 
e appropriate. Our data support this. 
Despite the limitations of small sample size and retrospec- 
ive data collection, our data demonstrate a high readmission rate 
mongst patients with COVID-19 who received shorter courses of 
teroids. Further research is required to establish the optimal dura- 
ion of steroids and how to identify patients who require ongoing 
teroids at discharge. 
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